Tardive dykinesia is a movement disorder that can cause involuntary and sometimes uncontrollable movements in the face, tongue, neck, arms and legs. It is sometimes referred to as “involuntary movement disorder” or “associated movement disorder.” While it is not a life-threatening condition, it can be extremely uncomfortable and even embarrassing for those who suffer from it. In this blog post, we will explore what tardive dykinesia looks like, its causes and its treatment options. We will also discuss what medical professionals should look out for if they suspect their patient may be suffering from this condition.
Tardive dykinesia is a neurological disorder that is characterized by involuntary, repetitive movements of the tongue, lips, and face. The condition can also affect the arms, legs, and trunk. Tardive dykinesia typically occurs in people who have been taking antipsychotic medications for an extended period of time. The exact cause of tardive dykinesia is unknown, but it is thought to be related to changes in the brain that are caused by the antipsychotic medication. Treatment for tardive dykinesia typically involves discontinuing the use of the offending antipsychotic medication. In some cases, other medications may be used to help control the symptoms of tardive dykinesia.
Tardive dykinesia (TD) is a condition that causes involuntary, repetitive movements of the face, tongue, or extremities. The exact cause of TD is unknown, but it is believed to be related to the long-term use of antipsychotic medications. TD typically occurs in people who have been taking antipsychotics for six months or longer. In some cases, TD may occur after just a few weeks of treatment.
There are several possible mechanisms by which antipsychotic medications may cause TD. One theory is that these drugs block dopamine receptors in the brain. Dopamine is a neurotransmitter that plays an important role in movement and learning. By blocking dopamine receptors, antipsychotic medications may interfere with the brain’s ability to control muscle movement.
Another theory is that antipsychotic medications may damage neurons in the basal ganglia, a region of the brain involved in motor control. Antipsychotics have also been shown to increase levels of the neurotransmitter glutamate. Excess glutamate activity has been linked to the development of TD and other neurological conditions.
It’s important to note that not all people who take antipsychotic medications will develop TD. The risk appears to be highest among older adults and those who have underlying medical conditions that affect brain function. People who have a family history of TD are also at increased risk.
Tardive dykinesia is a neurological disorder that is characterized by involuntary, repetitive movements of the face, mouth, tongue, or body. The exact cause of tardive dykinesia is unknown, but it is believed to be related to the use of certain antipsychotic medications. Treatment for tardive dykinesia typically involves the use of anticholinergic medications or botulinum toxin injections. In some cases, tardive dykinesia may resolve on its own over time.
Prevention of tardive dykinesia (TD) is possible through early recognition and treatment of the underlying causes. Risk factors for developing TD include certain medications, older age, female gender, mental illness, and substance abuse.
In summary, tardive dykinesia is an involuntary movement disorder caused by long-term use of antipsychotic medications. While it can affect any person who takes these medications for a prolonged period, women and elderly persons are more susceptible to developing this condition. It is important for medical professionals to be aware of the risk factors associated with tardive dykinesia in order to provide appropriate diagnosis and treatment options. With proper management strategies such as medication adjustment or alternative therapies, individuals suffering from TD can experience relief from their symptoms and improve their quality of life.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Cancer research in the US is world class. With the government pulling out, its future is uncertain
2.
On all CAR-T products, the FDA is calling for a new boxed warning.
3.
Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.
4.
Win for Perioperative Durvalumab in Muscle-Invasive Bladder Cancer
5.
Novel Treatment Shows Promise for Oral Mucositis Caused by Radiation.
1.
Advancements in Cancer Treatment Strategies for Non-Hodgkin Lymphoma
2.
A Breakthrough in Multiple Myeloma: Darzalex Delays Disease Progression by 51%
3.
The Growing Challenge of Haematological Malignancies in Older Adults
4.
Value, Access, and Affordability in Next-Gen Oncology: Navigating Costs, Coverage, and Clinical Impact
5.
Cold Antibody AIHA and Neoplastic Disorders: Unraveling the Clinical and Pathogenic Link
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
2.
Thromboprophylaxis In Medical Settings- An Update
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation